Medigen Vaccine Biologics Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 218.29 million compared to TWD 2.09 million a year ago. Net loss was TWD 52.03 million compared to TWD 309.26 million a year ago. Basic loss per share from continuing operations was TWD 0.16 compared to TWD 0.95 a year ago.
For the nine months, sales was TWD 218.29 million compared to TWD 341.31 million a year ago. Net loss was TWD 577.7 million compared to TWD 757.42 million a year ago. Basic loss per share from continuing operations was TWD 1.76 compared to TWD 2.35 a year ago.